Tag: HP-MAP
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Featured Article
The economic forces driving manufacturing’s next cycle
Australia’s manufacturing sector entered 2026 with improving momentum, but renewed global disruption is again testing resilience across the industry.
